We are live on ! Find out more
MIRM icon

Mirum Pharmaceuticals
MIRM

43 hedge funds and large institutions have $260M invested in Mirum Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 21 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

425% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 4

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

10% more funds holding

Funds holding: 39 → 43 (+4)

2.6% more ownership

Funds ownership: 70.68% → 73.28% (+2.6%)

35% less capital invested

Capital invested by funds: $398M → $260M (-$138M)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
43
Holders Change
+4
Holders Change %
+10.26%
% of All Funds
0.95%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.04%
New
9
Increased
21
Reduced
4
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
PC
Polar Capital
United Kingdom
+$12.6M
2
SI
Sofinnova Investments
California
+$6.87M
3
BBA
Baker Bros. Advisors
New York
+$4.1M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$3.86M
5
Axa
Axa
France
+$2.57M

Top Sellers

1
O
OrbiMed
New York
-$1.75M
2
RJA
Raymond James & Associates
Florida
-$217K
3
LC
Lindbrook Capital
California
-$49K
4
Ensign Peak Advisors
Ensign Peak Advisors
Utah
-$46.8K
5
Morgan Stanley
Morgan Stanley
New York
-$46.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$58.6M – – –
FM
2
Frazier Management
Washington
$49.9M – – –
DM
3
Deerfield Management
New York
$48.3M – – –
NHAS
4
Novo Holdings A/S
Denmark
$34.2M – – –
RSCM
5
Rock Springs Capital Management
Maryland
$17.4M -$32.8K -2,000 -0.2%
PC
6
Polar Capital
United Kingdom
$10.8M +$12.6M +769,425 New
BBA
7
Baker Bros. Advisors
New York
$8.17M +$4.1M +250,000 +75%
SI
8
Sofinnova Investments
California
$5.86M +$6.87M +418,589 New
BC
9
Boxer Capital
California
$4.44M – – –
BlackRock
10
BlackRock
New York
$3.59M +$1.24M +75,566 +42%
Fidelity Investments
11
Fidelity Investments
Massachusetts
$3.29M +$3.86M +235,000 New
Vanguard Group
12
Vanguard Group
Pennsylvania
$2.43M +$1.53M +93,344 +116%
Axa
13
Axa
France
$2.19M +$2.57M +156,751 New
Alyeska Investment Group
14
Alyeska Investment Group
Illinois
$2.04M +$1.95M +118,631 +438%
Millennium Management
15
Millennium Management
New York
$1.33M +$1.2M +73,026 +328%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$1.31M +$571K +34,790 +59%
Northern Trust
17
Northern Trust
Illinois
$978K +$382K +23,294 +50%
EGI
18
EAM Global Investors
California
$969K +$143K +8,728 +14%
WVP
19
Worth Venture Partners
New Jersey
$755K +$439K +26,764 +99%
EI
20
EAM Investors
California
$754K +$116K +7,046 +15%
State Street
21
State Street
Massachusetts
$703K +$450K +27,409 +120%
Goldman Sachs
22
Goldman Sachs
New York
$534K +$626K +38,117 New
Squarepoint
23
Squarepoint
New York
$488K +$572K +34,866 New
Bank of New York Mellon
24
Bank of New York Mellon
New York
$240K +$92.2K +5,620 +49%
UBS Group
25
UBS Group
Switzerland
$238K +$200K +12,183 +253%
1
2

MIRM Hedge Fund Activity: Q1 2020 in Review

43 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q1 2020, worth a combined $260M — down 35% from $398M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new MIRM positions and 5 closed out — a net gain of 4 holders — while 21 added to existing stakes and 4 trimmed.

The largest buyer was Polar Capital, opening a new position worth an estimated $12.6M. The largest seller was OrbiMed, exiting entirely with an estimated $1.75M sold.

  • 43 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q1 2020, up from 39 in Q4 2019.
  • Funds reported $260M of Mirum Pharmaceuticals stock for Q1 2020, down 35% quarter-over-quarter.
  • 9 funds opened new Mirum Pharmaceuticals positions in Q1 2020 and 5 closed out, a net change of +4 holders.
  • The largest Mirum Pharmaceuticals buyer in Q1 2020 was Polar Capital, an estimated $12.6M added.
  • The largest Mirum Pharmaceuticals seller in Q1 2020 was OrbiMed, an estimated $1.75M sold.

Based on aggregated 13F filings for Q1 2020.